DNA as a Possible Target for Antitumor Ruthenium(III) Complexes

Synthesis, characterization and interaction of a new chiral trinuclear complex [bis(aquodiaminotryptophanato) CuII–Sn2IV]chloride with calfthymus DNA

“…Ruthenium(III) complexes interact with their likely biological targets, i.e. DNA and proteins in particular with transferrin and albumin [14]. Although they show significantly smaller conformational modification of the DNA double helix, they bind tightly to plasma protein with a marked preference for surface imidazole groups.…”

Synthesis, Characterization and Analysis of Leishmanicide Ability of the Compound [Ru(Cl)<sub>3</sub>(H<sub>2</sub>O)<sub>2</sub>(gly)]

“…In 1969, the antitumor activity of metallic complexes containing cisplatin was discovered (Katsaros and Anagnostopoulou 2002) [4] enabling the development of new antitumor drugs such as complexes involving organic metals and/or inorganic platinum, ruthenium and rhodium (PAULA et al 2005; Waxman and Anderson 2001) [5] [6]. Gallori and colleagues suggest that compounds containing ruthenium can bind to the DNA molecule, and that this interaction can alter the cell cycle, causing cell death through mechanisms such as apoptosis (Gallori et al 2000) [7]. Evidence also suggests that several ruthenium complexes interact with specific proteins.…”

In vitro and in vivo activity and cross resistance profiles of novel ruthenium (II) organometallic arene complexes in human ovarian cancer

“…Transport and sequestration of Ru into tumour cells may be mediated via protein transport and receptor mediated uptake (Guo and Sadler, 1999). Due to differing ligand geometry between their complexes, Ru compounds bind to DNA forming predominately inter-strand crosslinks as opposed to the intra-strand crosslinks favoured by cisplatin Gallori et al, 2000). In addition, non-nuclear targets, such as the mitochondrion and the cell surface, have also been implicated in the antineoplastic activity of Ru complexes, particularly in the case of the clinically investigated Ru(III) antimetastatic drug (trans-RuCl 4 (DMSO)Im)(ImH) (NAMI-A) (Bergamo et al, 2000).…”